Reportedly, the World Health Organization (WHO) expert panel has backed the use of Merck & Co Inc’s (MRK) COVID-19 antiviral pill for high-risk patients. The expert panel conditionally recommended the pill, molnupiravir, for patients with the non-severe disease with a high risk of hospitalization, such as the unvaccinated, immunocompromised, older people, and also those with chronic diseases. The recommendation came based on new data from six clinical trials involving 4,796 patients.
The recommendations from the WHO’s Guideline Development Group (GDG) help doctors to provide the best care for patients in situations such as the COVID-19 pandemic. The panel informed that young and healthy patients, including children, and pregnant or breastfeeding women should not be given molnupiravir due to potential risks such as defects in a developing fetus, as reported in animal studies.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Stay Informed! Stay Competitive! Please join us at Vista Partners to receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
